<DOC>
	<DOC>NCT02640482</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of ABT-493/ABT-530 in adults with genotype 2 chronic hepatitis C virus (HCV) infection.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>Screening laboratory result indicating hepatitis C virus (HCV) Genotype2 (GT2) infection. Chronic HCV infection. Subject must be HCV treatmentna√Øve or have failed previous HCV treatment. Subject must be noncirrhotic. History of severe, lifethreatening or other significant sensitivity to any excipient of the study drugs. Female who is pregnant, planning to become pregnant during the study, or breastfeeding; or male whose partner is pregnant or planning to become pregnant during the study. Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator. Positive test result at Screening for hepatitis B surface antigen (HBsAg) or antihuman immunodeficiency virus antibody (HIV Ab). HCV genotype performed during screening indicating coinfection with more than 1 HCV genotype.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Treatment-Naive</keyword>
	<keyword>Hepatitis C Virus Genotype 2</keyword>
	<keyword>Sofosbuvir (SOF)-Experienced</keyword>
	<keyword>Treatment-Experienced</keyword>
	<keyword>Non-cirrhotic</keyword>
</DOC>